Tharimmune Seeks Shareholder Approval for Highly Dilutive Equity Issuances and Expanded Incentive Plan

summarizeSummary

Tharimmune, Inc. is calling a special meeting to approve several proposals that would result in substantial dilution, including the issuance of shares for strategic advisor and cryptocurrency warrants, restricted stock units, and a significant increase in its equity incentive plan.

check_boxKey Events

• Strategic Advisor Warrants Approval

  Shareholder approval is sought for the issuance of shares underlying Strategic Advisor Warrants, representing 5.0% of the company's fully diluted common stock after a recent private placement. The CEO and President are affiliated with the lead strategic advisor receiving these warrants, which have a nominal exercise price of $0.001.

• Cryptocurrency Pre-Funded Warrants Approval

  The company is asking shareholders to approve the issuance of shares upon the exercise of Cryptocurrency Pre-Funded Warrants, issued in connection with a November 2025 private placement. These warrants, with an exercise price of $0.0001, effectively represent millions of shares that will be issued at a minimal cost.

• Equity Incentive Plan Expansion

  Shareholders are asked to approve an amendment to the 2023 Omnibus Equity Incentive Plan, increasing the number of shares available for issuance by 7,000,000. This represents a significant potential future dilution and an overhang on the stock.

• Advisor Restricted Stock Units Approval

  Approval is requested for the issuance of 162,601 Restricted Stock Units (RSUs) to Clear Street LLC, a placement agent, in connection with the November 2025 private placement offering.

auto_awesomeAnalysis

Tharimmune, Inc. is requesting shareholder approval for multiple proposals that, if passed, would result in substantial dilution to existing shareholders. The company is seeking to issue millions of shares through strategic advisor warrants, cryptocurrency pre-funded warrants, and restricted stock units for a placement agent, all at nominal exercise prices. Cumulatively, these proposals, along with a significant 7,000,000 share increase to the equity incentive plan, represent a potential dilution of over 45% relative to current outstanding shares. This level of dilution is highly material and could significantly impact shareholder value. The involvement of the CEO and President with the lead strategic advisor receiving warrants further highlights the insider benefit from these dilutive transactions.